Research & Development

Maruho and X-Chem announce drug discovery collaboration

X-Chem has announced today a drug discovery partnership with Maruho to discover lead compounds for novel and challenging targets with applications for human diseases.

Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.

Insilico Medicine develops AI-based drug discovery platform

US biotech company Insilico Medicine has developed a new artificial intelligence (AI) system for drug discovery, known as GENTRL.

Vertex to acquire US biotech firm Semma Therapeutics for £785m

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type 1 diabetes.

HiFiBiO Therapeutics closes £55m Series C financing

HiFiBiO Therapeutics, a US biotherapeutics company, which has developed a single-cell analytics platform for extensive immune profiling, has completed a $67m (£54.86m) Series C financing round.

Immatics, Celgene sign £1.3bn deal to develop cancer immunotherapies

Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers.

OncoNano awarded £12.6m grant from Cancer Prevention and Research Institute of Texas

OncoNano Medicine, Inc. today announced that it has been awarded $15.4m (£12.6m) from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates.

Zogenix to acquire Modis Therapeutics in £325m deal

Zogenix has agreed to acquire Modis Therapeutics, a California-based biopharma company focused on developing disease-modifying therapies for rare genetic diseases, in a cash-cum-stock deal worth over $400m (£325.72m).

ADC Therapeutics and Freenome enter biomarker development collaboration

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine).